Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 SAN FRANCISCO, Aug. 7, 2023 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy…

Click here to view original post

Advertisement — Advertise with Biotech Networks